Beyond Spring Pharma Stock
Nevertheless, pantginis rates beyondspring a. (bysi) stock news and headlines to help you in your trading and investing decisions.
Revenue forecast of us$912.7k unchanged since last update.
Beyond spring pharma stock. Shares of beyondspring ( nasdaq:bysi) soared on wednesday after the pharmaceutical company released promising clinical trial results for. Learn more on how bysi compares to other companies It's therefore worth looking at beyondspring's earnings history below.
In china, we own a 57.97% interest in our chinese subsidiary, dalian wanchunbulin pharmaceuticals ltd. A stock market crash can be a harrowing experience to endure, and watching the value of your portfolio fall can cause temptations to sell. The closing price, day’s high, day’s low, and day’s volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above.
Beyondspring stock price target raised to $95 from $30 at evercore isi. Analysts like beyondspring stock less than the stock of other medical companies. Beyondspring now will take its case to the u.s.
4, 2021 at 10:29 a.m. The closing price above is not necessarily indicative of future price. The strong outlook of beyondspring's lung cancer drug has bysi stock moving up august 4, 2021 by nick clarkson , web editor aug 4, 2021, 12:55 pm est august 4, 2021
If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. Beyondspring pharmaceuticals shares were down 30% to $16.05 after the company said its phase 3 registrational trial of plinabulin in combination with docetaxel versus docetaxel alone for the. Bysi beyondspring inc — stock price and discussion | stocktwits.
Since then, bysi stock has decreased by 60.9% and is now trading at $4.44. Get the latest beyondspring, inc. Press release reported on 11/24/21 that.
(“wanchunbulin”), which owns a 100% interest in plinabulin. 1 we own global rights to plinabulin in all countries except china. Pantginis predicts beyondspring will lose $2.16 per share this year, and $1.91 per share next year.
The company’s stock price has collected 7.73% of gains in the last five trading sessions. Bysi), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a. Biotechs industry in the us expected to see average net income decline 10.0% next year.
It had slid 27% in the six months through tuesday. Nasdaqcm:bysi earnings and revenue growth october 14th 2021. The actual price is not adjusted for splits or dividends.
The stock recently traded at $27.11, compared with its tuesday close at $9.63. The consensus rating for beyondspring is hold while the average consensus rating for medical companies is buy. Consensus price target down from us$64.
The consensus outlook for 2021 has been updated. Of course, the future is what really matters. Beyondspring inc nasdaq updated nov 20, 2021 12:59 am.
Komentar
Posting Komentar